NDA 021527 · Boehringer Ingelheim
Atrovent Hfa
Ipratropium Bromide · Inhalation
Last checked: Nov 20, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Nov 17, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
125
33 Phase 3, 4 recruiting
FAERS reports
36,013
27,436 serious, 4,745 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2025.
ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ATROVENT HFA is an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema ( 1 )
Mechanism: Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ATROVENT HFA · IPRATROPIUM BROMIDE 0.021MG/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ipratropium" as an intervention, any sponsor and status, largest first.
- Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00400153 · 1,480 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: Atrovent Respimat (20 mcg); COMBIVENT MDI (36/206 mcg) and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 180 sites in all
- Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02177253 · 1,118 participants · Start Oct 2002 · Primary completion Mar 2004
Drug: Ipratropium bromide / Salbutamol; Placebo Inhalation solution and 3 more · For: Pulmonary Disease, Chronic Obstructive
- A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible BronchoscopyPivotal-lookingStatus unknown
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT06376942 · 1,050 participants (planned) · Start Apr 24, 2024 · Primary completion Apr 25, 2025
Drug: Glycopyrronium; Ipratropium · For: Subjects Undergoing Flexible Bronchoscopy
Sites: Chandigarh, India
- The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency RoomPivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT01524198 · 945 participants · Start Nov 2010 · Primary completion Apr 2012
Drug: Budesonide; Normal saline · For: Status Asthmaticus
Sites: Riyadh, Saudi Arabia
- Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02173782 · 892 participants · Start Feb 1998 · Primary completion Apr 1999
Drug: Berodual® Respimat ® high dose; Berodual® Respimat ® low dose and 2 more · For: Pulmonary Disease, Chronic Obstructive
- Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.Pivotal-lookingCompleted
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT03738917 · 668 participants · Start Feb 1, 2019 · Primary completion Nov 30, 2021
Drug: Dextromethorphan 15 milligrams; Ipratropium Bromide 20Micrograms Inhaler · For: Acute Bronchitis
Sites: Badalona, Spain; Balaguer, Spain; Barcelona, Spain · 12 sites in all
- Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092989 · 650 participants · Start Jul 2004 · Primary completion Mar 2007
Drug: montelukast sodium; placebo · For: Asthma
- Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02177344 · 646 participants · Start Aug 1998 · Primary completion Oct 1999
Drug: Low dose of Ipratropium bromide; High dose of Ipratropium bromide and 2 more · For: Pulmonary Disease, Chronic Obstructive
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea6,130
- asthma4,095
- pneumonia3,215
- cough3,117
- drug ineffective2,757
- wheezing2,691
- fatigue2,285
- nausea2,040
- chronic obstructive pulmonary disease1,882
- off label use1,781
- diarrhoea1,733
- malaise1,724
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 946 |
| 2005 | 1,232 |
| 2006 | 912 |
| 2007 | 805 |
| 2008 | 979 |
| 2009 | 1,006 |
| 2010 | 1,009 |
| 2011 | 1,198 |
| 2012 | 1,181 |
| 2013 | 1,068 |
| 2014 | 1,184 |
| 2015 | 1,440 |
| 2016 | 1,832 |
| 2017 | 1,624 |
| 2018 | 2,101 |
| 2019 | 2,339 |
| 2020 | 2,745 |
| 2021 | 2,663 |
| 2022 | 2,005 |
| 2023 | 1,813 |
| 2024 | 2,137 |
| 2025 | 2,103 |
| 2026 | 1,687 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Atrovent HFA (Ipratropium Bromide)
2024 spending
$115M
Beneficiaries
62,582
200,254 claims
Per beneficiary
$1,842
$36.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $131,773,398 |
| 2021 | $133,670,253 |
| 2022 | $134,769,804 |
| 2023 | $131,864,275 |
| 2024 | $115,305,947 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Use of inhaled/nebulised ipratropium bromide in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2-agonist and systemic steroid in the management of acute asthma exacerbations: a systematic review and meta-analysis of randomised controlled trials.
Hamud AA, Mudawi K, Powell C, et al. · Arch Dis Child 2026 · Systematic Review, Meta-Analysis
- Ipratropium.
· Med Lett Drugs Ther 1987 · Clinical Trial, Comparative Study
- Effectiveness of antitussives, anticholinergics, and honey versus usual care in adults with uncomplicated acute bronchitis: a multiarm randomized clinical trial.
Llor C, Moragas A, Ouchi D, et al. · Fam Pract 2023 · Randomized Controlled Trial, Multicenter Study
- Ipratropium Bromide Nasal Spray in Non-Allergic Rhinitis: A Systematic Review and Meta-Analysis.
El Khoury P, Abou Hamad W, Khalaf MG, et al. · Laryngoscope 2023 · Meta-Analysis, Systematic Review
- Inhaled magnesium sulfate in the treatment of acute asthma.
Knightly R, Milan SJ, Hughes R, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.